These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36124339)
1. Apremilast and biologics: Characteristics of patients treated with apremilast before, during, or after a biological treatment. Pinto-Pulido EL; Lario AR; Vega-Díez D; González-Cañete M; García-Verdú E; Polo-Rodríguez I; Piteiro-Bermejo AB; Medina-Montalvo S; Trasobares-Marugán L Dermatol Ther; 2022 Nov; 35(11):e15844. PubMed ID: 36124339 [TBL] [Abstract][Full Text] [Related]
2. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis. Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018 [TBL] [Abstract][Full Text] [Related]
3. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis. Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418 [TBL] [Abstract][Full Text] [Related]
4. Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink. Persson R; Cordey M; Paris M; Jick S Drug Saf; 2022 Nov; 45(11):1403-1411. PubMed ID: 36151359 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue. Takamura S; Sugai S; Taguchi R; Teraki Y J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729 [TBL] [Abstract][Full Text] [Related]
6. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Palfreeman AC; McNamee KE; McCann FE Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359 [TBL] [Abstract][Full Text] [Related]
7. Four-year drug survival of apremilast in patients with psoriasis. Kishimoto M; Komine M; Kamiya K; Sugai J; Kuwahara A; Ohtsuki M J Dermatol; 2023 Jul; 50(7):960-963. PubMed ID: 36938674 [TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. Wu JJ; Pelletier C; Ung B; Tian M J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520 [TBL] [Abstract][Full Text] [Related]
9. Safety evaluation of apremilast for the treatment of psoriasis. Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578 [TBL] [Abstract][Full Text] [Related]
10. Apremilast and its role in psoriatic arthritis. Sandhu VK; Eder L; Yeung J G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680 [TBL] [Abstract][Full Text] [Related]
11. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis. Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641 [TBL] [Abstract][Full Text] [Related]
12. Real-world use of apremilast for patients with psoriasis in Japan. Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of apremilast in psoriatic arthritis: Focus on skin manifestations and special populations. Balato A; Campione E; Cirillo T; Malara G; Trifirò C; Bianchi L; Fabbrocini G Dermatol Ther; 2020 May; 33(3):e13440. PubMed ID: 32306448 [TBL] [Abstract][Full Text] [Related]
14. Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland. Koskivirta I; Ruotsalainen J; Kurki S; Lakkakorpi P; Salminen-Mankonen H; Pirilä L; Harvima R; Palomäki A Scand J Rheumatol; 2023 Sep; 52(5):549-555. PubMed ID: 36644971 [TBL] [Abstract][Full Text] [Related]
15. ▼ Apremilast for psoriasis and psoriatic arthritis. Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317 [TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Kawalec P; Holko P; Moćko P; Pilc A Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605 [TBL] [Abstract][Full Text] [Related]
17. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain. Queiro Silva R; Armesto S; González Vela C; Naharro Fernández C; González-Gay MA Dermatol Ther; 2020 Nov; 33(6):e13961. PubMed ID: 32618402 [TBL] [Abstract][Full Text] [Related]
19. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. Manfreda V; Esposito M; Campione E; Bianchi L; Giunta A Postgrad Med; 2019 Apr; 131(3):239-240. PubMed ID: 30700196 [TBL] [Abstract][Full Text] [Related]